Evolus (EOLS) Cut to “Sell” at Zacks Investment Research
Zacks Investment Research lowered shares of Evolus (NASDAQ:EOLS) from a hold rating to a sell rating in a research note issued to investors on Tuesday.
According to Zacks, “Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. “
Separately, Cantor Fitzgerald set a $35.00 price target on Evolus and gave the stock a buy rating in a research note on Thursday, September 27th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $30.40.
Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Monday, November 5th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.09). On average, equities analysts predict that Evolus will post -1.84 EPS for the current year.
In related news, Director David N. Gill bought 3,000 shares of the business’s stock in a transaction dated Friday, December 14th. The shares were purchased at an average cost of $12.77 per share, with a total value of $38,310.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Vikram Malik bought 7,800 shares of the business’s stock in a transaction dated Monday, December 17th. The stock was bought at an average cost of $13.04 per share, for a total transaction of $101,712.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 17,147 shares of company stock worth $228,880.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. SG Americas Securities LLC purchased a new stake in shares of Evolus in the second quarter worth $108,000. Wells Fargo & Company MN grew its stake in shares of Evolus by 860.3% in the third quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock worth $110,000 after acquiring an additional 5,325 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Evolus by 761.4% during the second quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock valued at $183,000 after purchasing an additional 5,794 shares in the last quarter. TIAA CREF Investment Management LLC lifted its holdings in shares of Evolus by 51.2% during the third quarter. TIAA CREF Investment Management LLC now owns 12,259 shares of the company’s stock valued at $228,000 after purchasing an additional 4,151 shares in the last quarter. Finally, Man Group plc bought a new position in shares of Evolus during the third quarter valued at $232,000. 24.40% of the stock is currently owned by hedge funds and other institutional investors.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Further Reading: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.